Skip to main content
. 2022 Apr 1;28(11):2237–2247. doi: 10.1158/1078-0432.CCR-21-2326

Figure 1.

Figure 1. Study design: Figure describes the study design followed in the phase Ib and phase II part of the trial.

Study design: Figure describes the study design followed in the phase Ib and phase II part of the trial. BID, twice a day; ENZ, enzalutamide; mCRPC, metastatic castration-resistant prostate cancer; n, number of patients; QD, every day; RR, response rate.